(MedPage Today) — NEW ORLEANS — Adding the PCSK9 inhibitor evolocumab (Repatha) to stable lipid-lowering therapy reduced major adverse cardiac events (MACE) in patients with atherosclerosis or high-risk diabetes, but without a history of myocardial…
Source link : https://www.medpagetoday.com/meetingcoverage/aha/118395
Author :
Publish date : 2025-11-09 17:17:00
Copyright for syndicated content belongs to the linked Source.
